These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15285301)

  • 1. Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
    Piura B; Rabinovich A
    Eur J Gynaecol Oncol; 2004; 25(4):449-52. PubMed ID: 15285301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
    Suprasert P; Cheewakriangkrai C; Manopunya M
    Asian Pac J Cancer Prev; 2012; 13(2):517-20. PubMed ID: 22524817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
    Piura B; Meirovitz M
    Eur J Gynaecol Oncol; 2005; 26(4):386-90. PubMed ID: 16122184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum.
    Silver DF; Piver MS
    Am J Clin Oncol; 1999 Oct; 22(5):450-2. PubMed ID: 10521056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
    Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
    Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
    Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
    Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
    Nagao S; Kogiku A; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
    J Ovarian Res; 2020 Feb; 13(1):14. PubMed ID: 32028974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.
    Piura B; Rabinovich A
    Int J Gynecol Cancer; 2005; 15(4):612-7. PubMed ID: 16014114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
    Matulonis UA; Berlin S; Ivy P; Tyburski K; Krasner C; Zarwan C; Berkenblit A; Campos S; Horowitz N; Cannistra SA; Lee H; Lee J; Roche M; Hill M; Whalen C; Sullivan L; Tran C; Humphreys BD; Penson RT
    J Clin Oncol; 2009 Nov; 27(33):5601-6. PubMed ID: 19826113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
    Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
    Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma.
    Tewari D; Monk BJ; Hunter M; Falkner CA; Burger RA
    Invest New Drugs; 2004 Nov; 22(4):475-80. PubMed ID: 15292718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
    Goff BA; Holmberg LA; Veljovich D; Kurland BF;
    Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
    Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
    Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    Griffiths RW; Zee YK; Evans S; Mitchell CL; Kumaran GC; Welch RS; Jayson GC; Clamp AR; Hasan J
    Int J Gynecol Cancer; 2011 Jan; 21(1):58-65. PubMed ID: 21178570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Cohen S; Schwartz M; Dottino P; Beddoe AM
    J Ovarian Res; 2019 Apr; 12(1):36. PubMed ID: 31027500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
    Seliger G; Mueller LP; Kegel T; Kantelhardt EJ; Grothey A; Groe R; Strauss HG; Koelbl H; Thomssen C; Schmoll HJ
    Int J Gynecol Cancer; 2009 Nov; 19(8):1446-53. PubMed ID: 20009905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
    Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly topotecan for recurrent platinum resistant ovarian cancer.
    Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
    Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
    Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
    Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
    Yoshino K; Hiramatsu K; Enomoto T; Fujita M; Ueda Y; Kimura T; Kobayashi E; Kiyohara Y; Tsutsui T; Kimura T
    Anticancer Res; 2012 Sep; 32(9):4029-33. PubMed ID: 22993355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.